Trial · NCT07592819
A Trial Using Transcriptomic Signatures to Personalize Neoadjuvant Chemotherapy (NAC) for Patients With Resectable Borderline Pancreatic Adenocarcinoma (PDAC)
NCT07592819, Not applicable, Not yet recruiting, Institut Paoli-Calmettes
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. A Trial Using Transcriptomic Signatures to Personalize Neoadjuvant Chemotherapy (NAC) for Patients With Resectable Borderline Pancreatic Adenocarcinoma (PDAC). Trials, record NCT07592819. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07592819
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Trial Using Transcriptomic Signatures to Personalize Neoadjuvant Chemotherapy (NAC) for Patients With Resectable Borderline Pancreatic Adenocarcinoma (PDAC)
- NCT number
- NCT07592819
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 367 participants, estimated
- Lead sponsor
- Institut Paoli-Calmettes
- Conditions
- Pancreas Adenocarcinoma (MSI-H), Pancreatic Cancer Resectable
- Interventions
- mFOLFIRINOX (modified FOLFIRINOX)
- First posted
- 2026-05-18
- Last updated
- 2026-05-18
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Primary Outcome Measure | From treatment initiation through 1 year | Event-Free Survival is defined as the time from the start of treatment to the occurrence of any of the following events: * disease progression, * failure to undergo pancreatic resection, * death from any cause, * grade IV febrile neutropenia or grade IV diarrhea occurring during neoadjuvant chemotherapy. Participants without an event will be censored at the date of last follow-up. |
| Secondary | Objective Response Rate (ORR) | During neoadjuvant chemotherapy (up to 16 weeks) | Percentage of participants achieving a complete response or partial response per RECIST 1.1 criteria. |
| Secondary | Overall Survival (OS) | From treatment initiation through study completion (up to 18 months) | Time from start of treatment to death from any cause. |
| Secondary | Progression-Free Survival (PFS) | From treatment initiation through study completion (up to 18 months) | For non-operated patients: time from treatment initiation to disease progression or death from any cause. |
| Secondary | Recurrence-Free Survival (RFS) | From treatment initiation through study completion (up to 18 months) | For operated patients: time from treatment initiation to first local or metastatic recurrence or death. |
| Secondary | Disease Control Rate (DCR) | During neoadjuvant chemotherapy (up to 16 weeks) | Percentage of patients achieving complete response, partial response, or stable disease. |
| Secondary | Tumor Regression Grade (TRG) | At time of surgery | Pathologic tumor response assessed using Ryan's simplified Tumor Regression Grade (TRG 1-3) on the resected primary tumor. |
| Secondary | Postoperative Complications (Clavien-Dindo Classification) | Within 60 days after surgery | Postoperative complications graded from I to V according to Clavien-Dindo. |
| Secondary | Time to Recurrence (TTR) | Up to 18 months | Time from treatment initiation to first recurrence (local or metastatic) or death related to cancer. |
| Secondary | Quality of Life (EORTC QLQ-C30 ) | From baseline through study completion (up to 18 months) | Change over time in the Global Health Status/Quality of Life scale of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30). |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07592819
GET https://conductscience.org/api/trials/v1/NCT07592819/registered